Download PDF
Pneumologie 2024; 78(05): 325-329
DOI: 10.1055/a-2206-5602
Serie Palliativmedizin

Palliativmedizinische Aspekte der Pneumo-Onkologie

Palliative aspects in pulmonary oncology
David Heigener
1   Zentrum für Pneumologie, Agaplesion Diakonieklinikum Rotenburg gGmbH, Rotenburg Wümme, Deutschland (Ringgold ID: RIN40688)
,
Sandra Delis
2   Klinik für Palliativmedizin, Klinik für Pneumologie, Helios Klinikum Emil von Behring Berlin-Zehlendorf, Berlin, Deutschland (Ringgold ID: RIN14958)
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Die Palliativmedizin ist integraler Bestandteil der Therapie des fortgeschrittenen und metastasierten Lungenkarzinoms. Die strukturierte palliativmedizinische Begleitung der Patienten ab Diagnosestellung führt zu einer deutlich verbesserten Lebensqualität und eventuell sogar zu einer Verlängerung der Überlebenszeit. Neben der Symptomkontrolle sollte auch die Krankheitsperspektive regelmäßig neu evaluiert und mit dem Patienten und seinen Zugehörigen offen kommuniziert werden.

Abstract

Palliative medicine is an essential part in the treatment of patients with advanced or metastatic NSCLC. A structured palliative approach beginning from diagnoses improves quality of life and maybe even prolong survival. Besides symptom control, the disease trajectory and prognosis should regularly be re-evaluated and discussed with the patient and his loved ones.

Schlüsselwörter

metastasiertes Lungenkarzinom - Palliativmedizin - Symptomkontrolle - Therapiebegrenzung

Keywords

metastatic lunc cancer - palliative care - symptom control - therapy limitation


Publication History

Received: 26 September 2023

Accepted after revision: 07 November 2023

Article published online:
11 December 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Howlader N, Forjaz G, Mooradian MJ. et al. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med 2020; 383: 640-649
    CrossrefPubMedSearch in Google Scholar
  • 2 Mouritzen MT, Carus A, Ladekarl M. et al. Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World Efficacy. Cancers (Basel) 2021; 13: 4846
    CrossrefPubMedSearch in Google Scholar
  • 3 Heigener DF, Reck M. Immunotherapy: the third wave in lung cancer treatment. Lancet Respir Med 2015; 3: 923-924
    CrossrefPubMedSearch in Google Scholar
  • 4 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7-30
    CrossrefPubMedSearch in Google Scholar
  • 5 Temel JS, Greer JA, Muzikansky A. et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733-742
    CrossrefPubMedSearch in Google Scholar
  • 6 Bruera E, Yennurajalingam S. Palliative care in advanced cancer patients: how and when?. Oncologist 2012; 17: 267-273
    CrossrefPubMedSearch in Google Scholar
  • 7 Schuette W. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms, Langversion 2.1. 2022; AWMF-Registernummer: 020/007OL.
    PubMed
  • 8 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). S3-Leitlinie: Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung. 1.0. Aufl. Leitlinienprogramm Onkologie der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF), Deutschen Krebsgesellschaft e.V. (DKG) und Deutschen Krebshilfe (DKH). 2015
    PubMedSearch in Google Scholar
  • 9 [Anonym]. Cancer pain relief. With a guide to opioid availability. 2nd. Aufl. Genova: WHO; 1996
    Search in Google Scholar
  • 10 Galbraith S, Fagan P, Perkins P. et al. Does the use of a handheld fan improve chronic dyspnea? A randomized, controlled, crossover trial. J Pain Symptom Manage 2010; 39: 831-838
    CrossrefPubMedSearch in Google Scholar
  • 11 Abernethy AP, McDonald CF, Frith PA. et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet 2010; 376: 784-793
    CrossrefPubMedSearch in Google Scholar
  • 12 Bausewein C, Booth S, Gysels M. et al. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. Cochrane Database Syst Rev 2008; 2: CD005623
    CrossrefPubMedSearch in Google Scholar
  • 13 Fearon K, Strasser F, Anker SD. et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12: 489-495
    CrossrefPubMedSearch in Google Scholar
  • 14 Martin L, Senesse P, Gioulbasanis I. et al. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol 2015; 33: 90-99
    CrossrefPubMedSearch in Google Scholar
  • 15 Lundholm K, Gelin J, Hyltander A. et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 1994; 54: 5602-5606
    PubMedSearch in Google Scholar
  • 16 Brisbois TD, Kock IH de, Watanabe SM. et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol 2011; 22: 2086-2093
    CrossrefPubMedSearch in Google Scholar
  • 17 Strasser F, Luftner D, Possinger K. et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 2006; 24: 3394-3400
    CrossrefPubMedSearch in Google Scholar
  • 18 Currow D, Temel JS, Abernethy A. et al. ROMANA 3: A phase 3 safety extension study of anamorelin in advanced non-small cell lung cancer (NSCLC) patients with cachexia. Ann Oncol 2017; 28: 1949-1956
    CrossrefPubMedSearch in Google Scholar
  • 19 Yennurajalingam S, Frisbee-Hume S, Palmer JL. et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 2013; 31: 3076-3082
    CrossrefPubMedSearch in Google Scholar
  • 20 Paulsen O, Klepstad P, Rosland JH. et al. Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial. J Clin Oncol 2014; 32: 3221-3228
    CrossrefPubMedSearch in Google Scholar
  • 21 White PD, Goldsmith KA, Johnson AL. et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet 2011; 377: 823-836
    CrossrefPubMedSearch in Google Scholar
  • 22 Molassiotis A, Bailey C, Caress A. et al. Interventions for cough in cancer. Cochrane Database Syst Rev 2015; 5: CD007881
    CrossrefPubMedSearch in Google Scholar
  • 23 Razzak R, Waldfogel JM, Doberman DJ. et al. Gabapentin for Cough in Cancer. J Pain Palliat Care Pharmacother 2017; 31: 195-197
    CrossrefPubMedSearch in Google Scholar
  • 24 Smith JA, Harle A, Dockry R. et al. Aprepitant for Cough in Lung Cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights. Am J Respir Crit Care Med 2021; 203: 737-745
    CrossrefPubMedSearch in Google Scholar
  • 25 Thakerar A, Simadri K, Alexander M. et al. Paroxetine for the treatment of intractable and persistent cough in patients diagnosed with cancer. J Oncol Pharm Pract 2020; 26: 803-808
    CrossrefPubMedSearch in Google Scholar
  • 26 McGarvey LP, Birring SS, Morice AH. et al. Efficacy and safety of gefapixant, a P2X(3) receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet 2022; 399: 909-923
    CrossrefPubMedSearch in Google Scholar
  • 27 Hetzel J, Bockeler M. Endoscopic treatment for tumorous obstructions of the tracheobronchial system: a comparison of available techniques. Pneumologie 2012; 66: 408-415
    Thieme ConnectPubMedSearch in Google Scholar
  • 28 Wilson LD, Detterbeck FC, Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med 2007; 356: 1862-1869
    CrossrefPubMedSearch in Google Scholar
  • 29 Cao S, Zou Y, Lyu T. et al. Safety and Efficacy of Stent Graft Implantation for Malignant Superior Vena Cava Syndrome. Heart Surg Forum 2021; 24: E952-E957
    CrossrefPubMedSearch in Google Scholar
  • 30 Wu Y, Li Y, Wang M. et al. Percutaneous Endovascular Stent Placement for Treatment of Malignant Superior Vena Cava Syndrome: A Retrospective Review. Ann Vasc Surg 2022; 80: 325-332
    CrossrefPubMedSearch in Google Scholar
  • 31 Bhatnagar R, Piotrowska HEG, Laskawiec-Szkonter M. et al. Effect of Thoracoscopic Talc Poudrage vs Talc Slurry via Chest Tube on Pleurodesis Failure Rate Among Patients With Malignant Pleural Effusions: A Randomized Clinical Trial. JAMA 2020; 323: 60-69
    CrossrefPubMedSearch in Google Scholar
  • 32 Olden AM, Holloway R. Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? A cost-effectiveness analysis. J Palliat Med 2010; 13: 59-65
    CrossrefPubMedSearch in Google Scholar
  • 33 Heigener D. Systemtherapie des NSCLC bei schlechtem Allgemeinzustand. Info Pneumologie und Allergologie 2022; 2: 8-11
    PubMedSearch in Google Scholar